Researchers create new anti-cancer drug

A team of University of Hawaii Cancer Center scientists led by James Turkson, Ph.D. have created a new type of anti-cancer drug named BP-1-102. The drug, which can be orally administered, targets a key protein that triggers the development of many types of cancer including lung, breast and skin cancers.

The development of BP-1-102 was guided by the research teams computer based molecular analysis of the cancer causing Stat 3 protein that causes cancer by promoting abnormal cell growth in otherwise healthy cells.

"The molecular structure of the hyperactive Stat3 protein basically resembles two cars that are joined together side-by-side," said Professor Turkson. "We then utilized a computer program that creates molecular models of potential drugs engaging in binding to the Stat3 protein to craft the BP-1-102 drug which literally pulls apart the Stat3 protein rendering it ineffective in causing cancer."

A unique feature of BP-1-102 is that it remains highly effective against cancer even when administered in oral form. Presently, most anti-cancer drugs require intravenous (IV) administration in a clinic or hospital setting which increases the financial, physical and emotional burdens on . In its experimental form, BP-1-102 has shown promise in treating breast and lung cancers.

Currently, breast and lung cancers are two of the most commonly diagnosed cancers accounting for nearly half a million cases per year in the United States with over 200,000 deaths attributed to these diseases. In Hawaii, there is an average of 1500 cases diagnosed and over 600 deaths attributed to breast and lung cancers every year.

Professor Turkson is a recent and welcomed addition to the UH Cancer Center faculty. His innovative and ground breaking research focuses on developing novel anticancer drugs based on targeting and apoptosis pathways. The research article is published in the May 22nd edition of the journal.

add to favorites email to friend print save as pdf

Related Stories

Protein KO stops tumour growth

Apr 19, 2011

(PhysOrg.com) -- Research published last week in the journal PNAS may have identified a promising new target for developing drugs against one of the most common types of lung cancer.

Small molecules block cancer gene

Mar 10, 2009

Finding molecules that block the activity of the oncogene Stat 3 (signal transducer and activator of transcription) required screening literally millions of compounds, using computers that compared the structure of the cancer-causing ...

Combination drug therapy urged to battle lung cancer

Feb 02, 2012

Combination drug therapy may be needed to combat non-small cell lung cancer (NSCLC), according to a study by the Translational Genomics Research Institute (TGen) and Van Andel Research Institute (VARI).

Recommended for you

Chromosome buffers hold key to better melanoma understanding

49 minutes ago

Buffers that guard against damage to the ends of chromosomes could hold the key to a better understanding of malignant melanoma – the deadliest form of skin cancer – according to new research from the University of Leeds.

Many throat cancer patients can skip neck surgery

5 hours ago

A new study shows that patients with human papillomavirus (HPV) – the same virus associated with both cervical and head and neck cancer – positive oropharyngeal cancer see significantly higher rates of complete response ...

User comments